search
Back to results

Performance and Adherence in Children Using Spacers (OUTER-SPACERS)

Primary Purpose

Asthma, Asthma in Children

Status
Recruiting
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Tailored education
Standard care education
Sponsored by
University Hospitals of North Midlands NHS Trust
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Asthma

Eligibility Criteria

6 Years - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Aged 6-18 years;
  • Attending secondary care with a diagnosis of asthma;
  • Willing and able to give fully informed consent, or, participants having an acceptable individual capable of giving consent on the participant's behalf (e.g. parent or guardian of a child under 16 years of age);
  • Able to perform lung function and exhaled nitric oxide measurements;
  • Take twice-daily preventer medication using a valved holding chamber (spacer device) i.e. inhaled corticosteroid with or without long-acting beta antagonist;
  • Willing and able to comply with the study procedures.

Exclusion Criteria:

  • Significant co-existing respiratory disease (e.g. cystic fibrosis);
  • Currently participating in another clinical trial of an investigational medicinal product or medical device;
  • Non-English speaker where translation facilities are insufficient to guarantee informed consent.

Sites / Locations

  • Robert James BowlerRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Standard Care (Control) Group

Tailored Education Group

Arm Description

Participants randomised to this group will receive usual care in terms of their education.

Participants randomised to this group will receive tailored education, which is additional to standard care.

Outcomes

Primary Outcome Measures

Overall adherence to inhaled treatment (the product of persistence (number of doses taken as prescribed) and technique)
Overall adherence

Secondary Outcome Measures

The proportion of children and young people with asthma who are eligible for participation within the study from secondary care via screening logs
Proportion eligible
Recruitment and attrition rates over the study via screening and enrolment logs
Recruitment and attrition
The success rate of obtaining data from the Smart spacer device
Success rate
Feedback from System Usability Score (SUS)
SUS
Feedback from Net Promoter Score (NPS)
NPS
Rate of device failure from any cause (including loss of device, inability to retrieve data from SD card)
Device failure
Asthma control test (ACT) or Childhood Asthma Control Test (c-ACT)
ACT
Asthma Control Questionnaire
ACQ
GINA control score
GINA
Salbutamol (rescue) use
Salbutamol use
Need for oral steroid burst
Oral steroid burst use
m-PAQLQ score
m-PAQLQ
FEV1 z score
FEV1 z
FeNO (ppb)
FeNO (ppb)
UKIG score
UKIG

Full Information

First Posted
April 20, 2022
Last Updated
May 10, 2023
Sponsor
University Hospitals of North Midlands NHS Trust
search

1. Study Identification

Unique Protocol Identification Number
NCT05366309
Brief Title
Performance and Adherence in Children Using Spacers
Acronym
OUTER-SPACERS
Official Title
OUtcome Following Tailored Education and Retraining: Studying Performance and Adherence in ChildrEn and Young People With Asthma: a Randomised Feasibility Study
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 1, 2022 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospitals of North Midlands NHS Trust

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Asthma is a common disease which causes swelling in the airways, making it difficult to breathe. Asthma is common in children, affecting 1 in 11 children in the UK. Asthma is treated with inhalers which reduce the swelling. If inhalers are taken correctly they can help keep symptoms under control, allowing asthma sufferers to go about their day with less chance of having an asthma attack. Many patients have been found to not take their inhalers correctly and either under use (which leads to poor control of symptoms) or over use (which leads to potential side effects). Although asthma in most patients can be controlled with inhalers, not using inhalers correctly is one of the most common causes of poor control. This is common in children and young people (CYP) with all severities of asthma, resulting in high burden on the families and healthcare systems. The biggest challenge facing doctors and nurses helping CYP with asthma is finding a way to ensure that they take the medication. Whilst there are many studies looking into inhaler use, there are no large studies about how inhalers are used between clinic visits in CYP with asthma. The Smart Spacer is monitoring device which allows doctors to monitor when and how effectively inhalers are being used. This study wants to find out how well this device works, how well and how often CYP are using their inhalers, and if tailored education improves asthma control. To do this, participants in the study will be randomly selected to have "tailored education" or "standard care education". The investigators are inviting 100 children and young people (CYP) aged 6-18 years who have asthma to join this study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma, Asthma in Children

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Standard Care (Control) Group
Arm Type
Active Comparator
Arm Description
Participants randomised to this group will receive usual care in terms of their education.
Arm Title
Tailored Education Group
Arm Type
Experimental
Arm Description
Participants randomised to this group will receive tailored education, which is additional to standard care.
Intervention Type
Other
Intervention Name(s)
Tailored education
Intervention Description
Tailored Education: A delegated investigator will review the SD memory card data and share the results with the participant and/or parent/guardian. The investigator will explain whether there are partial or critical errors to inhalation technique that have been recorded. The participant will be informed about their overall adherence; including how and when they used their asthma medications. If errors in medication use are identified, specific coaching will be provided to help eliminate errors.
Intervention Type
Other
Intervention Name(s)
Standard care education
Intervention Description
Participants randomised to this group will receive usual care in terms of their education.
Primary Outcome Measure Information:
Title
Overall adherence to inhaled treatment (the product of persistence (number of doses taken as prescribed) and technique)
Description
Overall adherence
Time Frame
From recruitment up until 12-16 weeks follow-up time point
Secondary Outcome Measure Information:
Title
The proportion of children and young people with asthma who are eligible for participation within the study from secondary care via screening logs
Description
Proportion eligible
Time Frame
From recruitment up until 12-16 weeks follow-up time point
Title
Recruitment and attrition rates over the study via screening and enrolment logs
Description
Recruitment and attrition
Time Frame
From recruitment up until 12-16 weeks follow-up time point
Title
The success rate of obtaining data from the Smart spacer device
Description
Success rate
Time Frame
From recruitment up until 12-16 weeks follow-up time point
Title
Feedback from System Usability Score (SUS)
Description
SUS
Time Frame
At 12-16 weeks follow-up time point
Title
Feedback from Net Promoter Score (NPS)
Description
NPS
Time Frame
At 12-16 weeks follow-up time point
Title
Rate of device failure from any cause (including loss of device, inability to retrieve data from SD card)
Description
Device failure
Time Frame
From recruitment to 12-16 weeks follow-up time point
Title
Asthma control test (ACT) or Childhood Asthma Control Test (c-ACT)
Description
ACT
Time Frame
From recruitment to 12-16 weeks follow-up time point
Title
Asthma Control Questionnaire
Description
ACQ
Time Frame
From recruitment to 12-16 weeks follow-up time point
Title
GINA control score
Description
GINA
Time Frame
From recruitment to 12-16 weeks follow-up time point
Title
Salbutamol (rescue) use
Description
Salbutamol use
Time Frame
From recruitment to 12-16 weeks follow-up time point
Title
Need for oral steroid burst
Description
Oral steroid burst use
Time Frame
From recruitment to 12-16 weeks follow-up time point
Title
m-PAQLQ score
Description
m-PAQLQ
Time Frame
From recruitment to 12-16 weeks follow-up time point
Title
FEV1 z score
Description
FEV1 z
Time Frame
From recruitment to 12-16 weeks follow-up time point
Title
FeNO (ppb)
Description
FeNO (ppb)
Time Frame
From recruitment to 12-16 weeks follow-up time point
Title
UKIG score
Description
UKIG
Time Frame
From recruitment to 12-16 weeks follow-up time point

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged 6-18 years; Attending secondary care with a diagnosis of asthma; Willing and able to give fully informed consent, or, participants having an acceptable individual capable of giving consent on the participant's behalf (e.g. parent or guardian of a child under 16 years of age); Able to perform lung function and exhaled nitric oxide measurements; Take twice-daily preventer medication using a valved holding chamber (spacer device) i.e. inhaled corticosteroid with or without long-acting beta antagonist; Willing and able to comply with the study procedures. Exclusion Criteria: Significant co-existing respiratory disease (e.g. cystic fibrosis); Currently participating in another clinical trial of an investigational medicinal product or medical device; Non-English speaker where translation facilities are insufficient to guarantee informed consent.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Robert Bowler
Phone
01782
Ext
671939
Email
robert.bowler@uhnm.nhs.uk
First Name & Middle Initial & Last Name or Official Title & Degree
Keira Watts
Phone
01782
Ext
671939
Email
Keira.Watts@uhnm.nhs.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Will Carroll
Organizational Affiliation
PI
Official's Role
Principal Investigator
Facility Information:
Facility Name
Robert James Bowler
City
Stoke-on-Trent
State/Province
Staffordshire
ZIP/Postal Code
ST44JJ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Robert J Bowler
Phone
+447592800964
Email
Robert.Bowler@uhnm.nhs.uk

12. IPD Sharing Statement

Learn more about this trial

Performance and Adherence in Children Using Spacers

We'll reach out to this number within 24 hrs